JP2017148051A - タンパク質精製プロセス中のウイルスの不活性化方法 - Google Patents
タンパク質精製プロセス中のウイルスの不活性化方法 Download PDFInfo
- Publication number
- JP2017148051A JP2017148051A JP2017055363A JP2017055363A JP2017148051A JP 2017148051 A JP2017148051 A JP 2017148051A JP 2017055363 A JP2017055363 A JP 2017055363A JP 2017055363 A JP2017055363 A JP 2017055363A JP 2017148051 A JP2017148051 A JP 2017148051A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- virus
- sample
- inactivation
- chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 251
- 238000000034 method Methods 0.000 title claims abstract description 227
- 230000008569 process Effects 0.000 title claims abstract description 89
- 230000000415 inactivating effect Effects 0.000 title claims abstract description 17
- 238000001742 protein purification Methods 0.000 title abstract description 16
- 230000002779 inactivation Effects 0.000 claims abstract description 170
- 230000003068 static effect Effects 0.000 claims abstract description 79
- 230000027455 binding Effects 0.000 claims abstract description 47
- 238000009739 binding Methods 0.000 claims abstract description 47
- 238000002156 mixing Methods 0.000 claims abstract description 47
- 238000000746 purification Methods 0.000 claims abstract description 46
- 238000010977 unit operation Methods 0.000 claims abstract description 39
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 168
- 102000004169 proteins and genes Human genes 0.000 claims description 168
- 238000010828 elution Methods 0.000 claims description 51
- 230000000937 inactivator Effects 0.000 claims description 26
- 238000001042 affinity chromatography Methods 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 18
- 238000005341 cation exchange Methods 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 238000005349 anion exchange Methods 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000005277 cation exchange chromatography Methods 0.000 claims description 7
- 239000012501 chromatography medium Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 238000011100 viral filtration Methods 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 238000005571 anion exchange chromatography Methods 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 67
- 239000000243 solution Substances 0.000 description 31
- 239000012530 fluid Substances 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- 239000011159 matrix material Substances 0.000 description 22
- 239000000463 material Substances 0.000 description 21
- 239000012535 impurity Substances 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 108060003951 Immunoglobulin Proteins 0.000 description 18
- 239000000872 buffer Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 102000018358 immunoglobulin Human genes 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 238000004113 cell culture Methods 0.000 description 17
- 239000003446 ligand Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 238000011210 chromatographic step Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 239000012504 chromatography matrix Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 238000005352 clarification Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 238000010924 continuous production Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 229960000074 biopharmaceutical Drugs 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000011211 chromatography process step Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000012541 Fractogel® Substances 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000011118 depth filtration Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 235000010633 broth Nutrition 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000004845 protein aggregation Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 241001492267 Alcelaphine gammaherpesvirus 1 Species 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000012605 Fractogel® EMD TMAE Substances 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012527 feed solution Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011062 flow through chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- -1 sulfopropyl Chemical group 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- 238000012784 weak cation exchange Methods 0.000 description 2
- 238000003989 weak cation exchange chromatography Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical group ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000034804 Product quality issues Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000012561 harvest cell culture fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013327 media filtration Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229940022007 naked DNA vaccine Drugs 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012776 robust process Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/40—Mixing liquids with liquids; Emulsifying
- B01F23/49—Mixing systems, i.e. flow charts or diagrams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
- B01F25/40—Static mixers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/80—Mixing plants; Combinations of mixers
- B01F33/81—Combinations of similar mixers, e.g. with rotary stirring devices in two or more receptacles
- B01F33/811—Combinations of similar mixers, e.g. with rotary stirring devices in two or more receptacles in two or more consecutive, i.e. successive, mixing receptacles or being consecutively arranged
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
- B01F35/20—Measuring; Control or regulation
- B01F35/21—Measuring
- B01F35/2132—Concentration, pH, pOH, p(ION) or oxygen-demand
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
- B01F35/71—Feed mechanisms
- B01F35/715—Feeding the components in several steps, e.g. successive steps
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10061—Methods of inactivation or attenuation
Abstract
Description
本発明はタンパク質精製プロセス中のウイルス不活性化の方法を提供し、これは、産業界でタンパク質精製中に現在用いられている方法と比較して幾つかの利点を有する。特に、本明細書に記載されている方法は、タンパク質精製プロセス中にウイルス不活性化工程を行うための大きなタンクまたは貯蔵器を使用することを不要にし、ウイルス不活性化に要する総時間を減少させ、タンパク質精製プロセス中のウイルス不活性化操作を行うのに必要な全物理的空間を減少させ、そしてこれは、精製プロセス全体における設備設置総面積を減少させる。
生物医薬の製造は、薬物の安全性のために、および米国食品医薬品局(FDA)により定められた基準を満たすために、(哺乳類細胞を含む動物由来成分に由来する)ウイルスの不活性化または除去を要する。典型的なプロセスは、必要な防御を累積的にもたらす幾つかのウイルス除去工程を含む。
本明細書中で用いる「スタティックミキサ」なる語は、2つの流体物質、典型的には液体(例えば、標的タンパク質を含有するサンプルまたは結合および溶出クロマトグラフィープロセス工程からの溶出液)を混合するための装置を意味する。該装置は、典型的には、円筒状(チューブ)ハウジング内に含有されるミキサ要素(非移動要素とも称される)を含む。全体的な系設計は、2つの流体流を該スタティックミキサ内に運搬するための方法を含む。該流体流が該ミキサ内を移動するにつれて、該スタティックミキサの非移動要素が該物質を連続的に混合する。完全な混合は、流体の特性、チューブ内径、ミキサ要素の数およびそれらの設計を含む多数の変数に左右される。本明細書に記載されている種々の実施形態においては、スタティックミキサはインラインで使用される。
ウイルス不活性化はウイルスを不活性または複製もしくは感染不能にし、これは、特に治療用を意図した標的分子の場合に重要である。したがって、ウイルス不活性化は、典型的に、タンパク質精製プロセス中、特に該タンパク質が治療用を意図したものである場合に用いられる。
ウイルスは、2つの主要メカニズム、すなわち、除去(例えば、濾過またはクロマトグラフィーによるもの)または不活性化(例えば、低いpH、界面活性剤または照射)により「排除」されうる。生物医薬ウイルス排除のための、規制機関による推奨は、FDAおよびEMEAにより発行されている幾つかの文書に見出されうる。
スタティックミキサはインライン混合のために他の産業において使用されているが、それらは医薬産業においては広くは使用されていない。なぜなら、プロセスが一般にバッチ形態で作動するからである。更に、インライン・バッファー混合および希釈技術はタンパク質精製プロセスに関しては記載されているが(例えば、TechniKrom,BioRadおよびGE Healthcareにより提供されている市販の系において)、特にウイルス不活性化は一般に大規模プロセス用のプールタンクにおいて行われるため、それはウイルス不活性化には使用されていない。
前記のとおり、本明細書に記載されている方法の幾つかの実施形態においては、有効なウイルス不活性化を達成するために、インライン・スタティックミキサが使用される。
本発明の幾つかの実施形態においては、ウイルス不活性化は、サージタンクを使用して達成される。
この代表的実験においては、MAbを含有する溶液中に添加されたレトロウイルスを低いpHでの短時間のインキュベーションにより不活性化する。この実験の目的は、高濃度のタンパク質(抗体)を含有する溶液における完全なレトロウイルス不活性化に要求されるpHおよび曝露時間を理解することである。X−MuLVを不活性化するのに要求される最小時間を3.1〜3.5の範囲のpHで決定する。該実験を試験管内で行う。スタティックミキサを使用して不活性化に関して試験される最長実験時間は5分である。
この代表的実験においては、ウイルス不活性化が全く生じないpHまたは不活性化が生じる最小pHをより良く理解するために、実施例1に記載されているのと同じプロトコールに従う。
この代表的実験においては、スタティックミキサを使用する高タンパク質(MAb)供給溶液における完全なレトロウイルス不活性化に要するpHおよび曝露時間を調べる。
この代表的実験においては、スタティックミキサを使用した場合に高タンパク質(MAb)供給溶液における完全なレトロウイルス不活性化に要求されるpHおよび曝露時間を調べる。実験装置を図1に示す。
この実験においては、種々の添加物、例えばカプリル酸、ならびに界面活性剤、例えばTriton X、Tweenおよびそれらの組合せを使用する場合のウイルス不活性化のための最小時間およびpH要件を決定するために、試験管内でウイルス不活性化を行う。
この代表的実験においては、ウイルス不活性化に要求される最小時間およびpHに対するMAbおよび塩濃度の効果を調べる。20mM 酢酸(pH3.2)を使用して、MAbを21.8g/Lに調製し、10M NaOHを使用してpH5.0まで滴定する。その溶液の伝導度は1.4mS/cmである。20mM 酢酸(pH3.2)で希釈することにより、より低い濃度を得、10M NaOHを使用してpH5まで滴定する。これらの溶液の伝導度は1.4mS/cmである。250mMの最終モル濃度までのNaClの添加により、高い塩溶液を調節する。インライン・スタティックミキサ装置を使用するウイルス不活性化のために、全ての溶液をpH3.6に調節する。結果を表VIIに要約する。
この代表的実験においては、スタティックミキサを使用するウイルス不活性化に対するpHの効果を調べる。IgGを、20mM 酢酸(pH3.2)を使用して9g/Lに調製し、ついで10M NaOHを使用して、pH5.0まで滴定する。ついで全ての溶液を、インライン・スタティックミキサを使用するウイルス不活性化のための所望のpHに調節する。結果を以下の表VIIIに要約する。
この代表的実験においては、ウイルス不活性化に対する温度の効果を調べる。一般に、インラインのウイルス不活性化は、より高温への溶液の曝露に特に適している。したがって、ウイルス不活性化に対する温度の効果を決定することが重要である。
この代表的実験においては、pH安定化を加速させるためのスタティックミキサの使用を調べた。一般に、pHがその所望の値に達するまでの時間は最小であることが望ましい。
この代表的実験においては、MAbの清澄化細胞培養をプロテインAクロマトグラフィーに付す。プロテインA溶出液を、約3カラム体積にわたる10個の別々の画分中に集める。各画分を別々に2つのpH値(3.3および3.6)に調節する。pHを所望の値に減少させるのに必要な酸の量およびついでpHを所望の値に増加させるのに必要な塩基を、本明細書に記載されているとおりに決定する。これらの量は画分によって異なる。なぜなら、MAbの量が異なれば、各サンプルに関する緩衝能も異なるからである。
この代表的実験においては、MAb産物の質に対する、より短い曝露時間の有益な効果を調べる。2つのモノクローナル抗体を、プロテインAクロマトグラフィーを用いて精製し、サンプルを試験管内に集め、直ちに種々のpH(すなわち、pH3、3.3、3.6および4)および時間(すなわち、1、2、5および15および90分)でインキュベートする。
Claims (20)
- サンプル中の1以上のウイルスを不活性化するための方法であって、
標的分子を精製するプロセスにおいて、サンプルが第1単位操作から第2単位操作へ流動する時にサンプルを1以上のウイルス不活性化因子と連続的に混合することを含む、方法。 - 第1単位操作が結合および溶出クロマトグラフィーを含み、第2単位操作がフロースルー精製プロセスを含む、請求項1記載の方法。
- 結合および溶出クロマトグラフィーがプロテインAアフィニティクロマトグラフィーを含む、請求項2記載の方法。
- フロースルー精製プロセスが、活性炭、アニオン交換クロマトグラフィー媒体、カチオン交換クロマトグラフィー媒体およびウイルス濾過媒体からなる群から選択される2以上のマトリックスを含む、請求項2記載の方法。
- サンプルがプロテインA溶出液を含む、請求項1記載の方法。
- 標的分子が抗体またはFc領域含有タンパク質である、請求項1記載の方法。
- 1以上のインライン・スタティックミキサを使用して、サンプルを1以上のウイルス不活性化因子と混合する、請求項1記載の方法。
- 1以上のサージタンクを使用して、サンプルを1以上のウイルス不活性化因子と混合する、請求項1記載の方法。
- 1以上のウイルス不活性化因子が、酸、塩、溶媒および界面活性剤からなる群から選択される、請求項1記載の方法。
- サンプルの流動が層流範囲内にある、請求項7記載の方法。
- プロテインA溶出液中の1以上のウイルスを不活性化する方法であって、1以上のインライン・スタティックミキサを使用して、溶出液を1以上のウイルス不活性化因子と混合することを含み、10分以内または5分以内または2分以内または1分以内に完全なウイルス不活性化が達成される、方法。
- プロテインA溶出液中の1以上のウイルスを不活性化する方法であって、サージタンクを使用して、溶出液を1以上のウイルス不活性化因子と混合することを含み、1時間以内または30分以内に完全なウイルス不活性化が達成される、方法。
- 1以上のウイルスを不活性化するための方法であって、
(a)標的タンパク質を含むサンプルをプロテインAアフィニティクロマトグラフィーに付して溶出液を得る工程、
(b)溶出液をインライン・スタティックミキサに連続的に移して、10分以下の持続時間にわたって1以上のウイルス不活性化因子を溶出液と混合する工程、
を含み、それにより、1以上のウイルスを不活性化する方法。 - プロテインAアフィニティクロマトグラフィープロセスをバッチ形態で行う、請求項13記載の方法。
- プロテインAアフィニティクロマトグラフィープロセスを連続形態で行う、請求項13記載の方法。
- プロセスが連続多カラムクロマトグラフィーを含む、請求項15記載の方法。
- 1以上のウイルス不活性化因子が酸である、請求項13記載の方法。
- 標的タンパク質が抗体である、請求項13記載の方法。
- 工程(b)からの排出物をフロースルー精製プロセス工程に連続的に移す工程を更に含む、請求項13記載の方法。
- フロースルー精製工程が、活性炭、アニオン交換媒体、カチオン交換媒体およびウイルスフィルターから選択される2以上のマトリックスを含む、請求項19記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261666145P | 2012-06-29 | 2012-06-29 | |
US61/666,145 | 2012-06-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015520259A Division JP6182210B2 (ja) | 2012-06-29 | 2013-06-13 | タンパク質精製プロセス中のウイルスの不活性化方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017148051A true JP2017148051A (ja) | 2017-08-31 |
JP6457575B2 JP6457575B2 (ja) | 2019-01-23 |
Family
ID=49783749
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015520259A Active JP6182210B2 (ja) | 2012-06-29 | 2013-06-13 | タンパク質精製プロセス中のウイルスの不活性化方法 |
JP2017055363A Active JP6457575B2 (ja) | 2012-06-29 | 2017-03-22 | タンパク質精製プロセス中のウイルスの不活性化方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015520259A Active JP6182210B2 (ja) | 2012-06-29 | 2013-06-13 | タンパク質精製プロセス中のウイルスの不活性化方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9809799B2 (ja) |
EP (2) | EP2867359B1 (ja) |
JP (2) | JP6182210B2 (ja) |
CN (2) | CN104411820B (ja) |
ES (1) | ES2895173T3 (ja) |
IN (1) | IN2014DN08526A (ja) |
SG (1) | SG11201406407TA (ja) |
WO (1) | WO2014004103A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102018112773A1 (de) | 2017-07-31 | 2019-01-31 | Subaru Corporation | Fahrzeugfahrsteuersystem |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2682168A1 (en) | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
WO2014137903A2 (en) * | 2013-03-08 | 2014-09-12 | Genzyme Corporation | Integrated continuous manufacturing of therapeutic protein drug substances |
TWI671312B (zh) | 2014-01-17 | 2019-09-11 | 美商健臻公司 | 無菌層析法及製法 |
TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
EP3131589B1 (en) * | 2014-04-15 | 2023-05-17 | Boehringer Ingelheim International GmbH | Method and use for continuously inactivating a virus during manufacture of a biological product |
JP6521351B2 (ja) * | 2014-10-14 | 2019-05-29 | テックプロジェクトサービス株式会社 | ウィルス不活化およびサンプリング装置 |
US11571635B2 (en) * | 2015-03-31 | 2023-02-07 | Cytiva Sweden Ab | Liquid chromatography system, a device, and a method |
WO2016207328A1 (en) * | 2015-06-24 | 2016-12-29 | Glycotope Gmbh | PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES |
JP7032046B2 (ja) * | 2016-01-22 | 2022-03-08 | 旭化成メディカル株式会社 | 生理活性物質の連続的な定流速精製方法 |
KR102550844B1 (ko) * | 2016-03-11 | 2023-07-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 단백질의 제조 동안 바이러스를 연속적으로 불활성화시키는 방법 |
CN105841984A (zh) * | 2016-03-18 | 2016-08-10 | 中国石油天然气股份有限公司 | 聚合物配注工艺设备检测评价装置 |
US11155794B2 (en) * | 2016-08-23 | 2021-10-26 | Alexion Pharmaceuticals, Inc. | Method of purifying a heterologous protein from an egg white |
CA3062516A1 (en) * | 2017-05-11 | 2018-11-15 | Emd Millipore Corporation | Mechanical method of maintaining narrow residence time distributions in continuous flow systems |
CA3062519A1 (en) * | 2017-05-11 | 2018-11-15 | Emd Millipore Corporation | Method of maintaining narrow residence time distributions in continuous flow systems using solid material packet interfaces |
GB201802593D0 (en) * | 2018-02-16 | 2018-04-04 | Fujifilm Diosynth Biotechnologies Uk Ltd | Rig |
WO2020046602A1 (en) | 2018-08-31 | 2020-03-05 | Genzyme Corporation | Sterile chromatography resin and use thereof in manufacturing processes |
US20220002679A1 (en) * | 2018-11-15 | 2022-01-06 | Bayer Healthcare Llc | Viral Inactivation Methods for Continuous Manufacturing of Antibodies |
US20220041650A1 (en) * | 2018-12-03 | 2022-02-10 | Duke University | Purification method for recombinant proteins and nanoparticles |
US20220098235A1 (en) * | 2019-01-23 | 2022-03-31 | Daiichi Sankyo Company, Limited | Methods for purifying antibodies comprising of a process by using activated carbon materials |
KR20210009982A (ko) * | 2019-07-18 | 2021-01-27 | 에이비온 주식회사 | 2당화된 인터페론-베타 단백질의 정제 방법 |
FR3099066B1 (fr) * | 2019-07-26 | 2021-08-13 | Novasep Process | Procédé de purification d’une substance cible avec inactivation virale |
WO2021197249A1 (zh) * | 2020-03-30 | 2021-10-07 | 上海复宏汉霖生物技术股份有限公司 | 一种用于靶分子连续纯化的系统和方法 |
EP4164780A1 (en) | 2020-06-16 | 2023-04-19 | Boehringer Ingelheim International GmbH | A method of providing a homogeneous feed stream within a plug flow reactor |
WO2023059800A2 (en) * | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6187631A (ja) * | 1984-10-02 | 1986-05-06 | キュノ、インコ−ポレ−テッド | 静脈内に注射可能な免疫グロブリンG(IgG)及びその製法 |
WO2011037522A1 (en) * | 2009-09-25 | 2011-03-31 | Ge Healthcare Bio-Sciences Corp | Separation system and method |
WO2012014183A1 (en) * | 2010-07-30 | 2012-02-02 | Pfizer Inc. | Tandem purification of proteins |
WO2012051147A1 (en) * | 2010-10-11 | 2012-04-19 | Abbott Laboratories | Processes for purification of proteins |
WO2012078677A2 (en) * | 2010-12-06 | 2012-06-14 | Tarpon Biosystems, Inc. | Continuous processing methods for biological products |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE69329108T2 (de) | 1992-03-02 | 2001-03-22 | Bioeng Inc | Verfahren zur inaktivierung von viren |
AU698154B2 (en) | 1993-06-23 | 1998-10-22 | New York Blood Center, Inc., The | System for viral inactivation of blood |
ATE542891T1 (de) | 1994-11-10 | 2012-02-15 | Baxter Healthcare Sa | Verfahren zur herstellung von biologischen produkten in protein-freier kultur |
US6686191B1 (en) | 1995-09-22 | 2004-02-03 | Bayer Healthcare Llc | Preparation of virally inactivated intravenously injectable immune serum globulin |
GB9611698D0 (en) | 1996-06-05 | 1996-08-07 | Iatros Ltd | Fluid processing |
AU737566B2 (en) * | 1997-04-08 | 2001-08-23 | Baxalta GmbH | An immunotolerant prothrombin complex preparation |
US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
DE19923027C2 (de) * | 1999-05-19 | 2002-09-19 | Aventis Behring Gmbh | Verfahren zur Inaktivierung von Viren |
US20030127603A1 (en) | 2001-05-15 | 2003-07-10 | Bernard Horowitz | Apparatus for the inactivation of pathogens in protein-containing fluids and uses thereof |
EP1415669A1 (en) | 2002-09-19 | 2004-05-06 | Aventis Behring GmbH | Process for sterilization of protein containing biological compositions |
AU2003300951A1 (en) | 2002-12-20 | 2004-07-22 | Baxter International Inc. | Fluid treatment method, apparatus and system |
US20040256329A1 (en) | 2003-06-13 | 2004-12-23 | Peter Meserol | Photodynamic biological fluid pathogen inactivation/filtering apparatus and method |
US8271139B2 (en) | 2003-10-17 | 2012-09-18 | Asahi Kasei Bioprocess, Inc. | Multi-stage accurate blending system and method |
WO2005090403A2 (en) | 2004-03-12 | 2005-09-29 | Biovest International, Inc. | Method and apparatus for antibody purification |
MX2007012499A (es) | 2005-04-11 | 2007-12-06 | Medarex Inc | Purificacion de proteinas. |
WO2009045897A1 (en) | 2007-10-03 | 2009-04-09 | Dyax Corp. | Systems and methods for purifying proteins |
US20110105725A1 (en) * | 2008-05-15 | 2011-05-05 | Novo Nordisk A/S | Antibody purification process |
JP5856845B2 (ja) * | 2008-10-20 | 2016-02-10 | アッヴィ・インコーポレイテッド | 抗体精製中におけるウイルスの不活性化 |
CA2932207A1 (en) | 2008-10-20 | 2010-12-09 | Abbvie Inc. | Isolation and purification of antibodies using protein a affinity chromatography |
SG195555A1 (en) | 2008-12-24 | 2013-12-30 | Emd Millipore Corp | Caustic stable chromatography ligands |
US9428548B2 (en) | 2009-09-01 | 2016-08-30 | Genentech, Inc. | Enhanced protein purification through a modified protein A elution |
SG186552A1 (en) | 2011-06-08 | 2013-01-30 | Emd Millipore Corp | Chromatography matrices including novel staphylococcus aureus protein a based ligands |
DK2732021T3 (da) * | 2011-07-08 | 2020-07-27 | Emd Millipore Corp | Forbedrede dybdefiltre til bioteknologiske engangsfremgangsmåder |
WO2013028330A2 (en) * | 2011-08-19 | 2013-02-28 | Emd Millipore Corporation | Methods of reducing level of one of more impurities in a sample during protein purification |
CN102492040B (zh) * | 2011-12-29 | 2014-06-25 | 嘉和生物药业有限公司 | 一种抗her2或/和抗her3抗体蛋白的纯化方法 |
EP2682168A1 (en) | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
WO2014137903A2 (en) | 2013-03-08 | 2014-09-12 | Genzyme Corporation | Integrated continuous manufacturing of therapeutic protein drug substances |
-
2013
- 2013-06-13 ES ES13810248T patent/ES2895173T3/es active Active
- 2013-06-13 US US14/390,924 patent/US9809799B2/en active Active
- 2013-06-13 JP JP2015520259A patent/JP6182210B2/ja active Active
- 2013-06-13 WO PCT/US2013/045677 patent/WO2014004103A1/en active Application Filing
- 2013-06-13 CN CN201380034780.5A patent/CN104411820B/zh active Active
- 2013-06-13 EP EP13810248.8A patent/EP2867359B1/en active Active
- 2013-06-13 CN CN201710252174.0A patent/CN107188926B/zh active Active
- 2013-06-13 SG SG11201406407TA patent/SG11201406407TA/en unknown
- 2013-06-13 EP EP21191783.6A patent/EP3981873A1/en active Pending
-
2014
- 2014-10-13 IN IN8526DEN2014 patent/IN2014DN08526A/en unknown
-
2017
- 2017-03-22 JP JP2017055363A patent/JP6457575B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6187631A (ja) * | 1984-10-02 | 1986-05-06 | キュノ、インコ−ポレ−テッド | 静脈内に注射可能な免疫グロブリンG(IgG)及びその製法 |
WO2011037522A1 (en) * | 2009-09-25 | 2011-03-31 | Ge Healthcare Bio-Sciences Corp | Separation system and method |
WO2012014183A1 (en) * | 2010-07-30 | 2012-02-02 | Pfizer Inc. | Tandem purification of proteins |
WO2012051147A1 (en) * | 2010-10-11 | 2012-04-19 | Abbott Laboratories | Processes for purification of proteins |
WO2012078677A2 (en) * | 2010-12-06 | 2012-06-14 | Tarpon Biosystems, Inc. | Continuous processing methods for biological products |
Non-Patent Citations (2)
Title |
---|
BIOLOGICALS, vol. 35, JPN6016044986, 2007, pages 343 - 347, ISSN: 0003781061 * |
WATER SCIENCE & TECHNOLOGY, vol. 53, no. 7, JPN6015050908, 2006, pages 199 - 207, ISSN: 0003781060 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102018112773A1 (de) | 2017-07-31 | 2019-01-31 | Subaru Corporation | Fahrzeugfahrsteuersystem |
Also Published As
Publication number | Publication date |
---|---|
US20150064769A1 (en) | 2015-03-05 |
CN107188926A (zh) | 2017-09-22 |
CN107188926B (zh) | 2021-02-09 |
CN104411820B (zh) | 2017-05-03 |
EP2867359A1 (en) | 2015-05-06 |
EP2867359A4 (en) | 2015-11-11 |
EP2867359B1 (en) | 2021-09-15 |
JP6457575B2 (ja) | 2019-01-23 |
US9809799B2 (en) | 2017-11-07 |
CN104411820A (zh) | 2015-03-11 |
JP6182210B2 (ja) | 2017-08-16 |
IN2014DN08526A (ja) | 2015-05-15 |
EP3981873A1 (en) | 2022-04-13 |
WO2014004103A1 (en) | 2014-01-03 |
SG11201406407TA (en) | 2014-11-27 |
JP2015522017A (ja) | 2015-08-03 |
ES2895173T3 (es) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6457575B2 (ja) | タンパク質精製プロセス中のウイルスの不活性化方法 | |
JP6471183B2 (ja) | 生体分子の精製 | |
Marichal‐Gallardo et al. | State‐of‐the‐art in downstream processing of monoclonal antibodies: Process trends in design and validation | |
KR101921552B1 (ko) | 사전 세정 단계를 이용하는 면역글로불린 정제 | |
JP7187436B2 (ja) | アフィニティークロマトグラフィー洗浄バッファー | |
Vunnum et al. | Protein A‐based affinity chromatography | |
Chahar et al. | Monoclonal antibody purification and its progression to commercial scale | |
KR20180004726A (ko) | 크로마토그래피 칼럼으로부터의 생성물의 연속 용리 방법 | |
US20150239956A1 (en) | High-affinity antibody and method for manufacturing the same | |
CA3124711A1 (en) | Automated biomanufacturing systems, facilities, and processes | |
WO2015118149A1 (en) | System, apparatus and method for anti-rsv antibodies and formulations | |
TW202102518A (zh) | 用於病毒滅活之替代性清潔劑 | |
US20220073560A1 (en) | Method for transferring a batch production process to a continuous production process | |
TWI686471B (zh) | 流體通道及連續流動系統中保持窄滯留時間分布的機械方法 | |
WO2022203044A1 (ja) | ウイルスクリアランス試験の方法 | |
JP2011041475A (ja) | 抗体製造方法 | |
Saab | Investigation the Plugging Behavior of Virus filters | |
AU2022280782A1 (en) | Titer method using uv measurement for continuous biological production | |
Lubiniecki et al. | Preparation of clinical trial supplies of biopharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181024 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181211 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181220 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6457575 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |